Radiation

TAE Life Sciences Awarded Patent for Borylated Amino Acid Compositions for Boron Neutron Capture Therapy

Retrieved on: 
Tuesday, March 12, 2024
Neutron, Radiation, Patent, Tyrosine, Research, BTS, Cancer, Ome, BNCT, Pharmaceutical industry

IRVINE, Calif., March 12, 2024 /PRNewswire/ -- TAE Life Sciences, a leading innovator in cancer treatment technologies, today announced that the United States Patent and Trademark Office (USPTO) has granted the company's U.S. Patent No. US 11,884,688 B2, for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT). This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant milestone in the field of radiation therapy.

Key Points: 
  • US 11,884,688 B2 , for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT).
  • This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant milestone in the field of radiation therapy.
  • "This patent represents a significant milestone for TAE Life Sciences, validating the innovative work of our research and development teams.
  • With this patent, TAE Life Sciences solidifies its position as a leader in radiation therapy innovation, poised to transform the landscape of cancer treatment.

Lamassu Awarded NIH Grant For Breakthrough Cancer Treatment

Retrieved on: 
Tuesday, March 12, 2024
Sarcoma, Principal, NCI, Radiation, MDM2, Disease, Patient, Research, National Cancer Institute, Cancer, NIH, IND, Cleveland Clinic, Clinical trial, Investigational New Drug, National Institutes of Health, Cleveland Clinic Children's, Hematology, Metastasis, Pharmaceutical industry

CLEVELAND, March 12, 2024 /PRNewswire/ -- Lamassu Bio Inc., a cutting-edge biotech company dedicated to innovative cancer therapies, has been awarded a grant from the  National Institutes of Health (NIH) and National Cancer Institute ( NCI) for the development of their groundbreaking treatment for p53 wild-type sarcomas. The $2.05 million grant will help fund the clinical trial integral to this new cancer treatment. The trial will be conducted in collaboration with Cleveland Clinic Taussig Cancer Center and Cleveland Clinic Children's Pediatric Hematology and Oncology Department.

Key Points: 
  • The $2.05 million grant will help fund the clinical trial integral to this new cancer treatment.
  • Its role in preventing tumor formation by inducing programmed cell death in response to cellular stress makes it a key target for cancer therapy.
  • This innovative approach offers promising prospects for addressing chemo-resistant cancer and presents a significant pathway for advancing cancer care.
  • "The NIH grant will play a pivotal role in facilitating the transition of our research from the laboratory to the bedside.

Apollo Hospitals Unveils South Asia's First ZAP-X, Transforming Brain Tumor Care

Retrieved on: 
Monday, March 11, 2024
Hospital, Neurology, Radiation, Apollo, Health, Anesthesia, Patient, Neoplasm, Stroke, Stereotactic surgery, Quality of life, Cancer, Apollo Hospitals, Medical imaging

ZAP-X introduces a new era in brain tumor treatment, offering patients a non-invasive, pain-free alternative with sessions lasting just 30 minutes.

Key Points: 
  • ZAP-X introduces a new era in brain tumor treatment, offering patients a non-invasive, pain-free alternative with sessions lasting just 30 minutes.
  • Dr Prathap Chandra Reddy, Founder Chairman, Apollo Hospitals Group said, "For four decades, Apollo Hospitals has pioneered healthcare, advancing exceptional care.
  • We pledge to democratize technology, making it accessible to all citizens and global communities, elevating standards of brain tumor treatment and ensuring better quality of life.
  • The Apollo Institute of Neurosciences pioneers neurological care in India and beyond, boasting advanced facilities and over 180,000 successful neurosurgeries.

Apollo Hospitals Unveils South Asia's First ZAP-X, Transforming Brain Tumor Care

Retrieved on: 
Monday, March 11, 2024
Hospital, Neurology, Radiation, Apollo, Health, Anesthesia, Patient, Neoplasm, Stroke, Stereotactic surgery, Quality of life, Cancer, Apollo Hospitals, Medical imaging

ZAP-X introduces a new era in brain tumor treatment, offering patients a non-invasive, pain-free alternative with sessions lasting just 30 minutes.

Key Points: 
  • ZAP-X introduces a new era in brain tumor treatment, offering patients a non-invasive, pain-free alternative with sessions lasting just 30 minutes.
  • Dr Prathap Chandra Reddy, Founder Chairman, Apollo Hospitals Group said, "For four decades, Apollo Hospitals has pioneered healthcare, advancing exceptional care.
  • We pledge to democratize technology, making it accessible to all citizens and global communities, elevating standards of brain tumor treatment and ensuring better quality of life.
  • The Apollo Institute of Neurosciences pioneers neurological care in India and beyond, boasting advanced facilities and over 180,000 successful neurosurgeries.

Godzilla x Kong: The New Empire – this Chinese-US blockbuster maximises the global appeal of the MonsterVerse

Retrieved on: 
Friday, April 5, 2024
Transformers, Titanic, Friends, Radiation, Logic, Apple, Noise, MonsterVerse, Character, Legendary Entertainment, Iwi, Trapping, City, Warner Bros., Heart, Bomb, Skar, Film industry

Seventy years after his first appearance in the 1954 Japanese film Gojira, Godzilla has become a global star.

Key Points: 
  • Seventy years after his first appearance in the 1954 Japanese film Gojira, Godzilla has become a global star.
  • Meanwhile King Kong, his gigantic Hollywood counterpart, has been circling the globe for a shade over 90 years.
  • The two come together in Godzilla x Kong: The New Empire for the second time in the MonsterVerse film franchise, this time as unlikely partners protecting the Earth.

Nuclear Godzilla

  • But by contrast, in the MonsterVerse, nuclear power stations and bombs are used routinely to “power up” Godzilla.
  • Godzilla not only absorbs the nuclear radiation from a power plant, but also turns quasi-cannibal, killing the sea-serpent Titan Tiamat to absorb its power.
  • Tiamat’s signature colour is pink, and so for the second half of Godzilla x Kong, Godzilla shines with rosy radioactive hues.

Kong goes subterranean

  • In Godzilla x Kong, King Kong is in Hollow Earth searching for his lost species.
  • In this way the film is something of a sequel to director Adam Wingard’s 2021 Godzilla vs Kong.
  • In it, Kong discovers an enslaved giant ape community near the heart of the Hollow Earth, under the control of the Skar King.
  • The city is burned, frozen and stomped on as Godzilla and Kong face off against their enemies.

Humour in Godzilla x Kong

  • Among the beloved national landmarks reduced to rubble is the Coliseum, which becomes a giant cat bed for Godzilla.
  • Aside from the Titans, Godzilla x Kong is largely populated by secondary characters from previous films, along with broadly drawn characters like Trapper, a dentist and vet for Titans (Dan Stevens on scene-chewing form).
  • However, in Godzilla x Kong it seems like the Titans are finally the main attraction in their own movies.
  • As Godzilla and Kong make themselves at home in semi-flattened cities all over the world, the global power of the MonsterVerse is hard to argue with.


Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.
Rayna Denison does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Retrieved on: 
Wednesday, March 6, 2024
Radiation, Doctor of Philosophy, Immunotherapy, News, FOLFIRINOX, Growth, CADL, PR, CXCR4, Lead, PRS, Multiple myeloma, Poster, Pancreatic cancer, Gemcitabine, Fast Track, Liver, Incidence, Cancer, City, HSC, Chung, TME, Overalls, FACP, Therapy, Sickle cell disease, Columbia University, MAPK, Immune system, SNF, G-CSF, Woman, AIO, SCD, AACR, PD-1, Conference, TILS, Tumor microenvironment, BioLineRx, Clinical trial, Survival, Oncology, Filgrastim, Collection, American Cancer Society, Caregiver, USD, SWI, MD, Blood, FDA, TSX, Biotechnology, Pancreatic Cancer Action Network, Stem cell, RAS, Valaciclovir, PDAC, Patient, Natalizumab, ONC, PEI, Pharmaceutical industry

Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.

Key Points: 
  • Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.
  • The American Cancer Society's estimates for pancreatic cancer in the United States for 2024 are: "About 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer.
  • Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths."
  • Biotech/oncology stocks targeting the growing global pancreatic cancer market have made headlines with recent developments and breakthroughs in treatments.

Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024

Retrieved on: 
Monday, March 11, 2024
Mallinckrodt Institute of Radiology, Neoplasm, Toxicity, Cancer, Perspective, Radiation, CATX, Peptide, Therapy

SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET.

Key Points: 
  • SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET.
  • To register, click here .
  • In addition, the Company’s management will discuss its next radiotherapy compound in development and provide an overview of its promising novel pretargeting technology.
  • A live question and answer session will follow the formal presentations.

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 7, 2024
Head, Restart, Neoplasm, Food, Government, Safety, Lawrence, Massachusetts, PMDA, Patient, Carcinoma, D&O, Brain, Lung cancer, Clinical trial, Alpha, G&A, Radiation, Pancreatic cancer, Liver disease, Pharmaceutical industry

We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.

Key Points: 
  • We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.
  • The Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumors.
  • Targeting completion of patient recruitment in the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma in H2 2024.
  • The Company expects that this cash balance will be sufficient to fund operations for at least two years.

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Retrieved on: 
Monday, March 4, 2024
Head, Neck, Recurrence, Toxicity, Anemia, Completeness, Radiation, SPECT/CT, Chemoradiotherapy, EBRT, Macroglobulinemia, Lymphocytopenia, Thrombocytopenia, Patient, Neutropenia, Survival, Poster, Cytopenia, Cancer, Pharmaceutical industry

The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).

Key Points: 
  • The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).
  • The data were presented in a poster at the 2024 Multidisciplinary Head and Neck Cancers Symposium held February 29-March 2, 2024, in Phoenix, AZ.
  • Complete remission was achieved in 64% of patients, with an ORR of 73% (n=11).
  • Observed adverse events were consistent with the known toxicity profile of iopofosine I 131, with cytopenias being the most common with all patients recovering.

The Driving Force Company PI Connection™ Introduces VMA® To Local Clinics as Exclusive Provider

Retrieved on: 
Monday, March 4, 2024
Isolate, Spine, DABCO, X-ray, Instability, FDA, Injury, DMX, Radiation, CPC, Health, Personal injury, Patient, Diagnosis

LOMBARD, Ill., March 04, 2024 (GLOBE NEWSWIRE) -- PI Connection™ from The Driving Force Company, https://drivingforcecompany.com , announced today that integrated healthcare clinics nationwide can now offer their patients groundbreaking, proprietary Vertebral Motion Analysis (VMA®) technology in-house.

Key Points: 
  • LOMBARD, Ill., March 04, 2024 (GLOBE NEWSWIRE) -- PI Connection™ from The Driving Force Company, https://drivingforcecompany.com , announced today that integrated healthcare clinics nationwide can now offer their patients groundbreaking, proprietary Vertebral Motion Analysis (VMA®) technology in-house.
  • “Unlike traditional x-rays and digital motion x-rays (DMX), VMA® technology captures real-time video quickly and accurately to detect injuries and instability in the spine,” states Dr. S. Scott Tauber, DC, DABCO, CPC of The Driving Force Company.
  • “It is the cost-effective, easy-to-use technology of the future that will help medical professionals provide better care for their patients.
  • “Several pain management and personal injury clinics have started using the state-of-the-art diagnostics powered by our exclusive VMA® medical equipment to provide better patient care and significantly increase net monthly revenue,” states Sam Frentzas, The Driving Force Company PI Connection Co-Founder.